RBC Capital Reiterates Outperform on Intellia Therapeutics, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating for Intellia Therapeutics, maintaining a price target of $54.
September 19, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Intellia Therapeutics, maintaining a price target of $54, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $54 price target by RBC Capital suggests a positive outlook for Intellia Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100